Investigators observed differing response rates between patients with upper tract primaries relative to patients with bladder primaries. They hypothesize that differences in the somatic mutational landscape between upper tract and lower tract tumors may explain the observed difference in response to FGFR targeted therapy. Specifically, of 67 evaluable patients, 59 had lower tract primaries, among whom infigratinib achieved a modest 22.0% response rate. However, among the 8 patients with upper tract primaries – noting the limitations of the small sample size – investigators identified 3 PRs and 1 CR for an overall response rate of 50.0%
Presented by: Nazli Dizman, MD, Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA
Written by: Michael Lattanzi, MD, Internal Medicine Resident, Department of Medicine, NYU School of Medicine, @MikeLattanzi at the 2019 ASCO Annual Meeting #ASCO19, May 31- June 4, 2019, Chicago, IL USA
References:
- Ross JS, Wang K, Khaira D, Ali SM, Fisher HA, Mian B, Nazeer T, Elvin JA, Palma N, Yelensky R, Lipson D. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer. 2016 Mar 1;122(5):702-11.
- Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JH. Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer discovery. 2018 Jul 1;8(7):812-21.